The multifaceted circulating endothelial cell in cancer: towards marker and target identification

By F. Bertolini, Y. Shaked, P. Mancuso, R. Kerbel. Nature Reviews. Cancer, 2006

600 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d1f199e0c1c2e8ba5051752893e08450c86be108

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Rakesh K. Jain
2. D. Hanahan
3. G. Bergers
4. D. Duda
5. Jay S. Loeffler
6. E. di Tomaso
7. P. Wen
8. Shahin Rafii

In Molecular Biology

1. Rakesh K. Jain
2. D. Hanahan
3. G. Bergers
4. D. Duda
5. Jay S. Loeffler
6. C. Lewis
7. R. Daneman
8. E. di Tomaso

In Oncology

1. Rakesh K. Jain
2. D. Hanahan
3. D. Duda
4. Jay S. Loeffler
5. C. Lewis
6. E. di Tomaso
7. D. Louis
8. B. Barres

Citations in the corpus

• The role of myeloid cells in the promotion of tumour angiogenesis (2008, background): “The possible role in tumour angiogenesis of other bone marrow-derived cells, such as platelets, endothelial progenitor cells and haematopoietic stem cells, has been discussed in detail elsewher”
• Modes of resistance to anti-angiogenic therapy (2008, background): “The fact that receptor tyrosine kinase inhibitors can transiently increase plasma levels of pro-angiogenic factors such as VEGF and placental growth factor (PlGF, also known as PGF ) has been previously recognized in the clinic, and even proposed as a predictive biomarker for tumour respons”
• The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. (2007, background): “The nature and exact functions of these mobilized BM-derived cells have been under intense scrutiny and are the subject of recent reviews [3,4].”
• Wnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis (2009, background): “Inhibition of Wnt/ -catenin signaling, or downstream targets, may prevent neovascularization in diabetic retinopathy and macular degeneration or disrupt the angiogenesis that drives growth of glioblastomas and other retinal or CNS tumors (29, 30).”
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007, background): “Viable CECs and CPCs have been previously proposed as biomarkers for antiangiogenic therapy, but a clear consensus on the surface markers used to identify these blood-circulating cells is currently lacking (Bertolini et al., 2006; Duda et al., 2006).”